Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$1.34 USD
-0.04 (-2.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.35 +0.01 (0.75%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Zentalis Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ZNTL 1.34 -0.04(-2.90%)
Will ZNTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 9th
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Other News for ZNTL
Zentalis management to meet with Oppenheimer
ZNTL Hosts Investor Meetings in Mid-July | ZNTL Stock News
Zentalis management to meet with Oppenheimer
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL ...
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting